IgA antibodies of coeliac disease patients recognise a dominant T cell epitope of A-gliadin
Open Access
- 1 September 2004
- Vol. 53 (9), 1274-1278
- https://doi.org/10.1136/gut.2003.032755
Abstract
Background: In coeliac disease (CD) patients, the dominant DQ2-Α-I-gliadin peptide recognised by CD4 T cells is contained within peptide sequence 57–73 (p57-73) of Α-gliadin. This peptide sequence is also located within a 33-mer protease resistant gliadin fragment and therefore is likely to play an important role in the pathogenesis of CD. Aims: Our aim was to determine whether a B cell epitope was present within the immunodominant T cell epitope of Α-gliadin and, if so, to elucidate its sequence and determine the importance of deamidation and/or modification of the amino acid at position 65 for IgA binding. Patients and methods: A cohort of CD patients, disease controls, and healthy individuals were examined. Serum IgA antibodies to the native and modified p57-73 fragment of Α-gliadin were analysed using enzyme linked immunosorbent assays. Peptide scanning experiments were further used to elucidate the B cell epitope. Results and conclusion: IgA antibodies to p57-73 were found in 29/72 (40.2%) endomysial antibody positive patients, all of whom had CD. The peptide antibody appeared to be present when patients were on a diet containing gluten and declined on a gluten free diet. The p57-73 antibody was very specific for CD (98%) and had a sensitivity of 56%. The amino acid at position 65 was not important for IgA binding but was crucial for T cell recognition of p57-73. Pentapeptide PXPQP emerges as a potentially strong candidate for the IgA binding motif in this region of Α-gliadin. This study shows that a significant proportion of newly diagnosed CD patients have an antibody response to the immunodominant T cell epitope.Keywords
This publication has 19 references indexed in Scilit:
- Structural Basis for Gluten Intolerance in Celiac SprueScience, 2002
- Gluten and the Gut--Lessons for Immune RegulationScience, 2002
- Celiac disease: antibody recognition against native and selectively deamidated gliadin peptides.2001
- Intranasal Administration of One Alpha Gliadin Can Downregulate the Immune Response to Whole Gliadin in MiceScandinavian Journal of Immunology, 2001
- Current approaches to diagnosis and treatment of celiac disease: An evolving spectrumGastroenterology, 2001
- B cell epitopes of gliadinClinical and Experimental Immunology, 2000
- Coeliac disease—a future for peptide therapy?The Lancet, 2000
- In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitopeNature Medicine, 2000
- Glutenin is involved in the gluten-driven mucosal T cell responseEuropean Journal of Immunology, 1999
- The widening spectrum of celiac diseaseThe American Journal of Clinical Nutrition, 1999